Voyager Therapeutics Reports Q2 2026 Financial Results, Collaboration Revenue Declines

Voyager Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $3.2 million, a decrease from $5.2 million in the same period last year. For the first half of 2026, total collaboration revenue was $5.8 million, down from $11.7 million in the prior year. The company continues to operate at a loss, with a net loss of $24.5 million for the quarter and $52.4 million for the six months ended June 30, 2026, compared to losses of $33.4 million and $64.4 million, respectively, in the same periods of 2025. The reduction in losses reflects a decrease in operating expenses, which fell to $29.6 million for the quarter from $41.8 million a year earlier, primarily due to lower research and development costs.

The company’s total operating expenses for the first half of 2026 were $62.4 million, down from $83.0 million in the same period of 2025. This decline is attributed to a strategic focus on prioritizing key programs and reducing headcount, which has led to lower employee-related expenses. Research and development expenses specifically decreased to $22.0 million for the quarter and $46.6 million for the half-year, down from $31.3 million and $62.9 million, respectively. The company noted that spending on its VY7523 program decreased as clinical trial enrollment was completed, while costs for the VY1706 program increased in preparation for its upcoming clinical trial.

As of June 30, 2026, Voyager Therapeutics had cash, cash equivalents, and marketable securities totaling $148.8 million, a significant decrease from $191.0 million at the end of 2025. The company’s total assets were reported at $197.8 million, down from $252.3 million at the end of the previous fiscal year. The decrease in cash and cash equivalents was primarily due to cash used in operating activities, which amounted to $59.3 million for the first half of 2026, compared to $71.2 million in the same period of 2025. The company anticipates that its existing cash reserves will be sufficient to meet its operational needs for at least the next twelve months.

In terms of strategic developments, Voyager Therapeutics is advancing its proprietary pipeline, which includes programs targeting neurological diseases such as Alzheimer’s and Friedreich’s ataxia. The company received FDA clearance for its Investigational New Drug application for VY1706, allowing it to initiate a clinical trial in early Alzheimer’s patients. Additionally, the company is collaborating with Neurocrine and Novartis on various gene therapy programs, which have provided over $500 million in non-dilutive funding to date. Voyager Therapeutics expects to continue leveraging these collaborations to support its research and development efforts while managing its expenses carefully.

Looking ahead, Voyager Therapeutics remains focused on its clinical trials and the development of its gene therapy programs. The company plans to initiate the clinical trial for VY1706 in the fourth quarter of 2026 and expects to provide updates on its progress. However, the company acknowledges the need for additional funding to support its ongoing operations and development activities, emphasizing that it may need to rely on equity offerings, collaborations, or other financing options to meet its future capital requirements.